Fingerprint
Dive into the research topics of 'Dermatologic adverse events to chemotherapeutic agents, Part 2: BRAF inhibitors, MEK inhibitors, and ipilimumab'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Dermatologic adverse events to chemotherapeutic agents, Part 2: BRAF inhibitors, MEK inhibitors, and ipilimumab
*Corresponding author for this work
Research output: Contribution to journal › Article › peer-review
21
Scopus
citations